机构

• 上海药物研究所 [35]
• 合肥物质科学研究院 [11]
• 广州生物医药与健康研... [7]
• 上海生物化学与细胞生... [3]
• 金属研究所 [2]

采集方式

• OAI收割 [58]

内容类型

• 期刊论文 [56]
• 会议论文 [1]
• 学位论文 [1]

发表日期

• 2023 [2]
• 2022 [4]
• 2021 [1]
• 2020 [3]
• 2019 [2]
• 2018 [8]
• 更多

学科主题

• Pharmacolo... [9]
• Chemistry [4]
• Biochemist... [2]
• 药物化学 [1]

筛选

浏览/检索结果: 共58条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment 期刊论文  OAI收割 MOLECULAR DIVERSITY, 2023, 页码: 20 作者:  Ding, Mengyuan;  Shen, Qianqian;  Lu, Wei;  Zhu, Shulei   |  收藏  |  浏览/下载：62/0  |  提交时间：2023/10/17 EGFR  HER2  NAMPT  Resistance  Selectivity  Molecular docking   Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo 期刊论文  OAI收割 JOURNAL OF CANCER, 2023, 卷号: 14, 期号: 1, 页码: 152-162 作者:  Lai, Mengzhen;  Zhang, Tao;  Chen, Hao;  Song, Peiran;  Tong, Linjiang   |  收藏  |  浏览/下载：80/0  |  提交时间：2023/04/10 fourth-generation EGFR inhibitor  EGFRC797S mutation  NSCLC  drug resistance  small molecular inhibitor   Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S)) 期刊论文  OAI收割 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 卷号: 72, 页码: 11 作者:  Fang, Haotian;  Wu, Yingming;  Xiao, Qitao;  He, Dongbo;  Zhou, Tongrui   |  收藏  |  浏览/下载：73/0  |  提交时间：2022/08/16 Non-small cell lung cancer  EGFR  Triple mutations  C797S  EGFR-TKIs   Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors 期刊论文  OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 233, 页码: 13 作者:  Tang, Qidong;  Peng, Ting;  Hu, Jie;  Zhang, Tao;  Chen, Pengqin   |  收藏  |  浏览/下载：30/0  |  提交时间：2022/08/16 Reversible  irreversible pan-HER inhibitor  Quinazolin-4-amine derivatives  Anti-tumor  Structure-activity relationship   Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation 期刊论文  OAI收割 ACS MEDICINAL CHEMISTRY LETTERS, 2022, 卷号: 13, 期号: 2, 页码: 278-283 作者:  Zhang, Hualin;  Xie, Ruliang;  AI-furas, Hawaa;  Li, Yupeng;  Wu, Qingxia   |  收藏  |  浏览/下载：26/0  |  提交时间：2022/06/15 NSCLC  acquired resistance  EGFR C797S  PROTACs  selectivity   Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR(T790M/C797S) Mutants 期刊论文  OAI收割 ACS MEDICINAL CHEMISTRY LETTERS, 2022, 页码: 7 作者:  Li, Shan;  Zhang, Tao   |  收藏  |  浏览/下载：25/0  |  提交时间：2022/06/15 Epidermal Growth Factor Receptor (EGFR)  Resistant Mutation  C797S  Antitumor   LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文  OAI收割 CANCER SCIENCE, 2021, 页码: 12 作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang   |  收藏  |  浏览/下载：87/0  |  提交时间：2022/01/18 C797S  epidermal growth factor receptor  fourth-generation EGFR TKI  non-small cell lung cancer  osimertinib resistance   Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation 期刊论文  OAI收割 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 卷号: 30, 期号: 16, 页码: 6 作者:  Su, Zhicheng;  Yang, Tingyuan;  Wang, Jie;  Lai, Mengzhen;  Tong, Linjiang   |  收藏  |  浏览/下载：62/0  |  提交时间：2020/12/24 EGFR  NSCLC  C797S   2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant 期刊论文  OAI收割 CHINESE CHEMICAL LETTERS, 2020, 卷号: 31, 期号: 5, 页码: 1281-1287 作者:  Hu, Xianglong;  Xun, Qiuju;  Zhang, Tao;  Zhu, Su-Jie;  Li, Qian   |  收藏  |  浏览/下载：79/0  |  提交时间：2020/07/01 EGFR(C797S) mutant  SARs  2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidine  Clinical resistance  Fourth-generation inhibitors   Design and synthesis of selective degraders of EGFR(L858R/T790M) mutant 期刊论文  OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 卷号: 192, 页码: 14 作者:  Zhang, Xin;  Xu, Fang;  Tong, Linjiang;  Zhang, Tao;  Xie, Hua   |  收藏  |  浏览/下载：68/0  |  提交时间：2020/07/01 Epidermal growth factor receptor (EGFR)  Resistance  Proteolysis targeting chimera (PROTAC)  Protein degradation